[{"address1": "175 Innovation Boulevard", "city": "Wilmington", "state": "DE", "zip": "19805", "country": "United States", "phone": "302 467 1280", "website": "https://preludetx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.", "fullTimeEmployees": 128, "companyOfficers": [{"maxAge": 1, "name": "Dr. Krishna  Vaddi D.V.M., Ph.D.", "age": 58, "title": "Founder, CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 905916, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Edna  Huang M.D.", "age": 51, "title": "President & Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 865629, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryant David Lim J.D.", "age": 52, "title": "CFO, Chief Legal Officer & Corporate Secretary", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 586425, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Aimee  Crombie Ph.D.", "title": "Senior VP and Head of Strategic Planning & Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Madhu  Pudipeddi Ph.D.", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peggy A. Scherle Ph.D.", "age": 62, "title": "Chief Scientific Officer", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 868617, "exercisedValue": 0, "unexercisedValue": 436567}, {"maxAge": 1, "name": "Ms. Michele  Porreca M.B.A.", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew P. Combs Ph.D.", "age": 58, "title": "Executive VP & Chief Chemistry Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 562461, "exercisedValue": 0, "unexercisedValue": 399432}, {"maxAge": 1, "name": "Mr. Naveen  Babbar Ph.D.", "title": "Senior Vice President of Translation Medicine", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William B. Novotny M.D.", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.7121, "open": 0.712, "dayLow": 0.712, "dayHigh": 0.7631, "regularMarketPreviousClose": 0.7121, "regularMarketOpen": 0.712, "regularMarketDayLow": 0.712, "regularMarketDayHigh": 0.7631, "payoutRatio": 0.0, "beta": 1.42, "forwardPE": -0.48741722, "volume": 81645, "regularMarketVolume": 81645, "averageVolume": 406066, "averageVolume10days": 153550, "averageDailyVolume10Day": 153550, "bid": 0.715, "ask": 0.7578, "bidSize": 2, "askSize": 2, "marketCap": 40505908, "fiftyTwoWeekLow": 0.67, "fiftyTwoWeekHigh": 6.8, "priceToSalesTrailing12Months": 13.501969, "fiftyDayAverage": 1.05492, "twoHundredDayAverage": 2.684545, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -94984112, "profitMargins": 0.0, "floatShares": 17656383, "sharesOutstanding": 42184900, "sharesShort": 3103542, "sharesShortPriorMonth": 3116988, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.056399997, "heldPercentInsiders": 0.094110005, "heldPercentInstitutions": 0.89918, "shortRatio": 13.46, "shortPercentOfFloat": 0.17899999, "impliedSharesOutstanding": 55035200, "bookValue": 2.843, "priceToBook": 0.25888148, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -131517000, "trailingEps": -1.77, "forwardEps": -1.51, "enterpriseToRevenue": -31.661, "enterpriseToEbitda": 0.671, "52WeekChange": -0.8259169, "SandP52WeekChange": 0.121255875, "quoteType": "EQUITY", "currentPrice": 0.736, "targetHighPrice": 5.0, "targetLowPrice": 1.0, "targetMeanPrice": 3.33333, "targetMedianPrice": 4.0, "recommendationMean": 2.25, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 153626000, "totalCashPerShare": 2.791, "ebitda": -141648000, "totalDebt": 18136000, "quickRatio": 6.913, "currentRatio": 7.037, "totalRevenue": 3000000, "debtToEquity": 11.594, "revenuePerShare": 0.04, "returnOnAssets": -0.39294997, "returnOnEquity": -0.66643995, "grossProfits": 3000000, "freeCashflow": -61550752, "operatingCashflow": -105722000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -11.45867, "financialCurrency": "USD", "symbol": "PRLD", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 3.356266, "regularMarketPrice": 0.736, "marketState": "CLOSED", "shortName": "Prelude Therapeutics Incorporat", "longName": "Prelude Therapeutics Incorporated", "corporateActions": [], "postMarketTime": 1741381215, "regularMarketTime": 1741381201, "exchange": "NMS", "messageBoardId": "finmb_373775974", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1601040600000, "postMarketChangePercent": 0.0, "postMarketPrice": 0.736, "postMarketChange": 0.0, "regularMarketChange": 0.023899972, "regularMarketDayRange": "0.712 - 0.7631", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 406066, "fiftyTwoWeekLowChange": 0.065999985, "fiftyTwoWeekLowChangePercent": 0.098507434, "fiftyTwoWeekRange": "0.67 - 6.8", "fiftyTwoWeekHighChange": -6.064, "fiftyTwoWeekHighChangePercent": -0.8917647, "fiftyTwoWeekChangePercent": -82.59169, "earningsTimestampStart": 1741604340, "earningsTimestampEnd": 1741953600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.77, "epsForward": -1.51, "epsCurrentYear": -1.77475, "priceEpsCurrentYear": -0.4147063, "fiftyDayAverageChange": -0.31891996, "fiftyDayAverageChangePercent": -0.30231673, "twoHundredDayAverageChange": -1.948545, "twoHundredDayAverageChangePercent": -0.72583807, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-09-25", "averageAnalystRating": "2.3 - Buy", "cryptoTradeable": false, "trailingPegRatio": null, "__fetch_time": "2025-03-08"}]